Global Fibrotic Diseases Treatment Market
시장 규모 (USD 10억)
연평균 성장률 :
% 
USD
5.79 Billion
USD
10.35 Billion
2024
2032
 예측 기간 |
2025 –2032 |
 시장 규모(기준 연도) |
USD 5.79 Billion |
 시장 규모(예측 연도) |
USD 10.35 Billion |
 연평균 성장률 |
% |
| 주요 시장 플레이어 |
|
Global Fibrotic Diseases Treatment Market, By Treatment (Medication, Organ Transplantation, Oxygen Therapy, and Others), Application (Idiopathic Pulmonary Fibrosis, Hepatic Cirrhosis, Renal Fibrosis, Cutaneous Fibrosis, and Others), End User (Hospitals, Specialty Clinics, Academic and Research Institutes, and Others) - Industry Trends and Forecast to 2032
Global Fibrotic Diseases Treatment Market Analysis
The rising prevalence of fibrotic diseases, such as idiopathic pulmonary fibrosis, hepatic cirrhosis, and renal fibrosis, is a significant driver of the global fibrotic diseases treatment Market. Factors such as aging populations, lifestyle changes, and increasing rates of chronic conditions like diabetes and hypertension are contributing to a higher incidence of these diseases. As the number of affected individuals grows, the demand for effective treatments intensifies, driving the need for advanced therapies, including antifibrotic drugs and biologics. Healthcare systems face growing pressure to manage chronic fibrotic conditions, driving demand for more effective treatments and fueling market growth.
Global Fibrotic Diseases Treatment Market Size
Data Bridge Market Research analyzes that the global fibrotic diseases treatment market is expected to reach USD 10.35 billion by 2032 from USD 5.79 billion in 2024, growing with CAGR of 7.6% during forecast period of 2025 to 2032.
Global Fibrotic Diseases Treatment Market Trends
“Rising Adoption of Biomarker-Based Diagnostics”
The use of biomarker-based diagnostics in Testicular Germ Cell Tumors (TGCT) is becoming more prevalent, with biomarkers such as alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (β-hCG), and lactate dehydrogenase (LDH) playing a crucial role in clinical practice. These biomarkers enable clinicians to achieve early detection, monitor disease progression, and tailor treatments to the individual characteristics of each patient. This trend reflects advancements in precision medicine and is leading to more accurate staging and risk stratification of TGCT. As research continues to identify additional biomarkers, the integration of these diagnostic tools is becoming a standard approach, enhancing treatment protocols and improving patient outcomes.
Global Fibrotic Diseases Treatment Market Segmentation
|
Attributes |
Global Fibrotic Diseases Treatment Market Insights |
|
Segments Covered |
|
|
적용 국가 |
미국, 캐나다, 멕시코, 도미니카 공화국, 자메이카, 파나마, 독일, 프랑스, 영국, 이탈리아, 스페인, 러시아, 터키, 네덜란드, 스위스, 헝가리, 리투아니아, 오스트리아, 아일랜드, 노르웨이, 폴란드, 유럽의 나머지 지역, 일본, 중국, 인도, 한국, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남, 대만, 아시아 태평양의 나머지 지역, 브라질, 에콰도르, 칠레, 콜롬비아, 베네수엘라, 아르헨티나, 페루, 퀴라소, 파라과이, 우루과이, 트리니다드 토바고, 남미의 나머지 지역, 남아프리카, 사우디 아라비아, UAE, 이집트, 쿠웨이트, 이스라엘, 바레인, 중동 및 아프리카의 나머지 지역 |
|
주요 시장 참여자 |
CH Boehringer Sohn AG & Co. KG. (독일), F. Hoffmann-La Roche Ltd (스위스), Teva Pharmaceutical Industries Ltd. (이스라엘), Sandoz International GmbH (독일), Accord Healthcare (영국), AbbVie Inc. (미국), Redx Pharma Pic (영국), Bristol-Myers Squibb Company (미국), BioMX (미국), KITHER BIOTECH SRL (이탈리아), Verona Pharma pic (영국), Intercept Pharmaceuticals, Inc. (미국) |
|
시장 기회 |
|
|
부가가치 데이터 정보 세트 |
Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 수입 수출 분석, 생산 능력 개요, 생산 소비 분석, 가격 추세 분석, 기후 변화 시나리오, 공급망 분석, 가치 사슬 분석, 원자재/소모품 개요, 공급업체 선택 기준, PESTLE 분석, 포터 분석 및 규제 프레임워크가 포함됩니다. |
글로벌 섬유성 질환 치료 시장 정의
섬유성 질환은 과도한 섬유성 결합 조직(섬유증)이 형성되는 상태로, 종종 만성 염증이나 조직 손상의 결과입니다. 이 비정상적인 조직 축적은 장기의 정상적인 기능을 방해하여 일반적으로 폐(폐 섬유증), 간(간 섬유증), 심장, 신장 및 피부에 영향을 미칩니다.
섬유성 질환에 대한 치료는 섬유증의 진행을 늦추거나 멈추고, 염증을 줄이고, 증상을 관리하는 데 중점을 둡니다. 접근 방식에는 항섬유증 약물, 면역 억제제, 생활 방식 수정, 그리고 진행된 경우 장기 이식과 같은 수술 옵션이 포함될 수 있습니다. 새로운 치료법은 섬유증 발병을 담당하는 특정 경로를 차단하는 표적 치료법을 탐구합니다.
글로벌 섬유성 질환 치료 시장 역학
운전자
- 섬유성 질환의 유병률 증가
특발성 폐섬유증, 간경변, 신장섬유증과 같은 섬유성 질환의 유병률 증가는 글로벌 섬유성 질환 치료 시장의 중요한 원동력입니다. 인구 고령화, 라이프스타일 변화, 당뇨병 및 고혈압과 같은 만성 질환의 증가율과 같은 요인이 이러한 질환의 발병률을 높이는 데 기여하고 있습니다. 영향을 받는 개인의 수가 증가함에 따라 효과적인 치료법에 대한 수요가 증가하여 항섬유화 약물 및 생물학적 제제를 포함한 고급 치료법에 대한 필요성이 커지고 있습니다. 의료 시스템은 만성 섬유성 질환을 관리해야 하는 압박이 커지고 있으며, 이는 보다 효과적인 치료법에 대한 수요를 촉진하고 시장 성장을 촉진합니다.
예를 들어,
- 2023년 1월 PubMed Central에 게재된 기사에 따르면 특발성 폐섬유증(IPF)의 발생률과 유병률이 전 세계적으로 증가하고 있으며, 더 이상 희귀 질환 분류에 맞지 않습니다. 북미에서 유병률은 10,000명당 2.4~2.98명이며, 한국은 10,000명당 4.51명으로 가장 높은 유병률을 보였습니다.
섬유성 질환의 유병률이 증가함에 따라 더 뛰어나고 접근성이 좋은 치료 솔루션에 대한 필요성이 부각되면서 시장이 크게 확대되고 있으며, 이 분야의 연구 개발도 더욱 촉진되고 있습니다.
- 담배를 피우는 사람의 수 증가
담배 흡연은 특발성 폐섬유증(IPF) 발병의 가장 잘 알려진 위험 요인 중 하나입니다. 게다가 최근 연구에 따르면 흡연은 IPF 환자의 생존에 부정적인 영향을 미칠 수 있다고 합니다. 흡연이 IPF의 발병에 기여하는 메커니즘은 거의 알려지지 않았습니다. 그러나 축적된 증거에 따르면 산화 스트레스가 증가하면 현재 흡연자이거나 과거 흡연자인 IPF 환자의 질병 진행이 촉진될 수 있습니다.
예를 들어,
- NCBI에서 발표한 기사에 따르면 2023년 6월 기준, 흡연은 특발성 폐섬유증(IPF)과 같은 간질성 폐질환(ILD)의 주요 위험 요인으로, 연구에 따르면 IPF 환자의 41%~83%가 흡연력이 있고 위험도가 60% 더 높은 것으로 나타났습니다.
- 2022년 5월, National Center for Biotechnology Information(NCBI)에 게재된 논문에 따르면, 흡연은 특발성 폐섬유증(IPF) 발병의 중요한 위험 요인으로 여겨졌습니다. 이 논문에서 수행한 연구에 따르면, 현재 흡연자와 과거 흡연자는 비흡연자보다 IPF 위험이 상당히 높았으며, aHR은 각각 1.66(95% CI 1.61~1.72)과 1.42(95% CI 1.37~1.48)였습니다. 현재 흡연자는 과거 흡연자보다 IPF 위험이 더 높았습니다(aHR 1.17, 95% CI 1.13~1.21). IPF 발병 위험은 흡연 강도와 기간이 증가함에 따라 증가했습니다.
기회
- 증가하는 연구 및 개발 활동
섬유성 질환의 유병률 증가와 더 효과적인 치료법에 대한 수요로 인해 제약 및 바이오 기술 회사는 R&D 투자를 늘리고 있습니다. 이러한 노력은 섬유증의 근본 원인을 표적으로 삼는 새로운 항섬유성 약물, 생물학적 제제 및 유전자 치료법을 포함한 혁신적인 치료법을 개발하는 것을 목표로 합니다. 또한 개인화된 의학 및 진단 기술의 발전으로 치료 결과와 전반적인 환자 관리가 개선될 것으로 예상됩니다. R&D가 진행됨에 따라 새로운 치료 옵션이 등장하여 시장 성장을 촉진하고 섬유성 질환 관리를 개선할 것입니다.
예를 들어,
- Boehringer Ingelheim International GmbH에 따르면 Boehringer Ingelheim은 2024년 5월 섬유성 염증성 질환에 대한 동종 최초의 치료법을 개발하기 위한 라이선스 계약을 확보했으며, 이는 환자 결과 개선을 목표로 하는 획기적인 치료법에 대한 의지를 강화합니다.
- 2021년 7월, Moez Ghumman et.al이 발표한 논문에 따르면, 기존의 경구 치료제인 피르페니돈과 닌테다닙은 증상을 완화하고 질병 진행을 늦춰 환자의 삶의 질을 개선하려고 시도할 수 있지만, 이러한 약물의 만성 복용량과 전신 투여는 심각한 부작용을 초래할 수 있습니다. 효과적인 치료 옵션이 부족하여 IPF에 대한 회복적 요법과 추가 완화적 요법에 대한 추가 조사가 필요합니다. 나노입자 기반 지속적 약물 전달 전략을 사용하면 부위별 치료와 장기 작용 요법을 위한 표적 전달을 보장하여 전반적인 환자 준수를 개선할 수 있습니다.
연구개발 활동의 증가는 혁신을 촉진하고 치료 전략을 개선함으로써 시장 확장을 가속화할 수 있는 중요한 기회를 제공합니다.
- 파이프라인 약물 개발의 진전
새로운 항섬유화 약물, 생물학적 제제, 유전자 요법을 포함한 점점 더 많은 유망한 치료법이 현재 다양한 개발 단계에 있습니다. 이러한 약물은 섬유화 질환의 근본 원인을 표적으로 삼아, 특히 특발성 폐 섬유증, 간경변, 신장 섬유증과 같은 질환에 대해 보다 효과적인 치료법과 개선된 환자 결과의 잠재력을 제공합니다. 이러한 약물의 성공적인 승인 및 상용화는 사용 가능한 치료 옵션의 범위를 확대하고, 더 나은 치료법에 대한 증가하는 수요를 충족하며, 시장 성장을 촉진할 것입니다.
예를 들어,
- 2024년 9월 폐섬유증재단이 발표한 기사에 따르면 현재 AP01, BBT-877, GKT137831 등의 약물이 섬유증 질환에 대한 2단계 개발 단계에 있다.
- NCBI에 따르면 2022년 2월, 2021년 2월에 시작된 1/2상 임상 시험은 테헤란의 탈레가니 병원에서 진행성 간 섬유증(3-4등급)에 대한 이마티닙(200mg/일)을 테스트하고 있습니다. 이 시험은 24주 동안 이마티닙과 표준 치료 및 위약을 비교합니다.
이 연구는 파이프라인 약물 개발의 진전을 강조하며, 잠재적으로 간 섬유증에 대한 새로운 치료법을 소개할 수 있으며, 이는 글로벌 섬유증 질환 치료 시장의 성장을 촉진할 수 있습니다.
파이프라인 약물 개발의 진전은 섬유성 질환 관리를 위한 혁신적인 솔루션을 제공함으로써 시장 확대를 크게 촉진할 것으로 예상됩니다.
제약/도전
- 높은 약물 및 치료 비용
섬유증 환자의 증가와 의료 기기 및 약물 가격 상승으로 인해 섬유증 질환 치료 비용이 점점 더 비싸지고 있습니다. 섬유증 치료에 사용되는 최신 기술 기기도 높은 치료 비용과 높은 정확도에 중요한 역할을 하며 특발성 폐 섬유증(IPF)에 대한 확실한 진단을 제공합니다. 따라서 섬유증 질환에 대한 약물 및 치료 절차의 높은 비용이 시장 성장을 방해하고 있습니다.
예를 들어,
- 2022년 10월 PubMed Central에 게재된 기사에 따르면, IPF에 대한 치료 옵션은 제한적이며, 경증에서 중등도의 경우 승인된 항섬유화제인 피르페니돈과 닌테다닙만 사용할 수 있습니다. 이러한 약물은 국가에 따라 1인당 월 2,000달러에서 14,000달러까지 비쌉니다.
- Alan Katz et.al이 발표한 논문에 따르면 2022년 9월 기준 고압산소요법 치료 비용은 세션 수와 서비스 위치를 포함한 몇 가지 요인에 따라 일반적으로 치료당 250~600달러 사이입니다.
- 2022년 1월, BMC Pulmonary Medicine에 게재된 기사에 따르면 피르페니돈의 연간 목록 가격은 약 36,070.80달러인 반면, 미국에서 피르페니돈과 닌테다닙의 연간 비용은 모두 100,000달러를 넘고 벨기에에서 닌테다닙의 연간 목록 가격은 약 28,910달러입니다. 이러한 높은 약물 및 치료 비용은 글로벌 섬유성 질환 치료 시장에 제약으로 작용하여 이러한 치료법에 대한 접근성을 제한하고 환자와 의료 시스템에 재정적 부담을 줄 것으로 예상됩니다.
섬유성 질환의 복합적이고 다인자적 특성
섬유증은 유전적 소인, 환경 노출, 기저 만성 질환을 포함한 다양한 요인에 의해 발생하므로 단일 원인을 정확히 파악하거나 모든 사람에게 맞는 치료법을 개발하기 어렵습니다. 이러한 복잡성은 섬유증에 관련된 다양한 메커니즘을 해결할 수 있는 효과적인 치료법 개발을 복잡하게 만듭니다. 또한 이러한 질병은 진행성이며 종종 무증상이기 때문에 조기 진단 및 치료가 더욱 복잡해져 개입이 지연됩니다.
예를 들어,
- 2023년 1월 PubMed Central에 게재된 기사에 따르면, IPF에서 정상 폐 조직이 비정상적인 기질 축적으로 대체되어 폐포 기능이 손상되고 호흡 부전으로 이어진다. 반복적인 미세 손상과 세포 복구 장애로 인해 돌이킬 수 없는 폐 손상이 발생한다
섬유성 질환은 다면적인 특성을 지니기 때문에 치료에도 고도로 맞춤화된 접근 방식이 필요하며, 제약 회사가 이러한 질환을 관리할 수 있는 보편적으로 효과적인 치료법과 전략을 개발하는 것은 어려운 일입니다.
글로벌 섬유성 질환 치료 시장 범위
시장은 치료, 응용 프로그램 및 최종 사용자를 기준으로 세분화됩니다. 이러한 세그먼트 간의 성장은 산업의 빈약한 성장 세그먼트를 분석하고 사용자에게 핵심 시장 응용 프로그램을 식별하기 위한 전략적 결정을 내리는 데 도움이 되는 귀중한 시장 개요와 시장 통찰력을 제공하는 데 도움이 됩니다.
치료별로
- 약물
- 닌테다닙(OFEV)
- 피르페니돈(ESBRIET)
- 장기 이식
- 산소 요법
- 기타
응용 프로그램으로
- 특발성 폐섬유증
- 간경변증
- 신장 섬유증
- 피부섬유증
- 기타
최종 사용자별
- 병원
- 전문 클리닉
- 학술 및 연구 기관
- 기타
글로벌 섬유성 질환 치료 시장 지역 분석
시장을 분석하고 시장 규모에 대한 통찰력과 추세를 제공하며, 치료, 응용 프로그램 및 최종 사용자를 다룹니다.
시장에서 다루는 국가는 미국, 캐나다, 멕시코, 도미니카 공화국, 자메이카, 파나마, 독일, 프랑스, 영국, 이탈리아, 스페인, 러시아, 터키, 네덜란드, 스위스, 헝가리, 리투아니아, 오스트리아, 아일랜드, 노르웨이, 폴란드, 기타 유럽, 일본, 중국, 인도, 한국, 호주, 싱가포르, 태국, 말레이시아, 인도네시아, 필리핀, 베트남, 대만, 기타 아시아 태평양, 브라질, 에콰도르, 칠레, 콜롬비아, 베네수엘라, 아르헨티나, 페루, 퀴라소, 파라과이, 우루과이, 트리니다드 토바고, 기타 남미, 남아프리카, 사우디 아라비아, UAE, 이집트, 쿠웨이트, 이스라엘, 바레인, 기타 중동 및 아프리카입니다.
북미는 잘 확립된 의료 인프라, 특발성 폐섬유증 및 간섬유증과 같은 섬유성 질환의 높은 유병률, 연구 개발에 대한 강력한 투자로 인해 우위를 점할 것으로 예상됩니다. 아시아 태평양은 의료 투자 증가, 섬유성 질환에 대한 인식 증가, 첨단 의료 치료법에 대한 접근성 개선으로 인해 가장 빠르게 성장하는 지역이 될 것으로 예상됩니다. 이 지역의 인구가 많고 고령화되어 있으며, 당뇨병 및 간 질환과 같은 섬유증과 관련된 만성 질환의 부담이 증가함에 따라 효과적인 치료법에 대한 수요가 더욱 증가합니다.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Global Fibrotic Diseases Treatment Market Share
The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.
Global Fibrotic Diseases Treatment Market Leaders Operating in the Market Are:
- C.H. Boehringer Sohn AG & Co. KG. (Germany)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sandoz International GmbH (Germany)
- Accord Healthcare (U.K.)
Latest Developments in Global Fibrotic Diseases Treatment Market
- In September 2024, Boehringer Ingelheim International GmbH announced that the FIBRONEER-IPF trial met its primary endpoint of FVC improvement at week 52, and it plans to submit a new drug application for nerandomilast for IPF treatment to the FDA and other global authorities. This successful trial and upcoming submission will strengthen Boehringer Ingelheim’s position in the competitive IPF market, potentially expanding its respiratory drug portfolio
- In July 2024, Teva and Sanofi announced an updated timeline for the anti-TL1A program, duvakitug, a monoclonal antibody targeting TL1A for moderate-to-severe IBD. Advancing this program strengthens both companies’ positions in the IBD treatment market, potentially expanding their offerings in immunology
- In November 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced a new collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives. This has helped the company to expand globally
- 2022년 3월, Roche Group의 일원인 Genentech는 광범위한 병기 소세포 폐암(ES-SCLC) 환자를 대상으로 초기(1차) 치료로 조사 중인 항-TIGIT 면역 요법 티라골루맙 플러스 테센트릭(아테졸리주맙)과 화학 요법(카르보플라틴 및 에토포사이드)을 평가하는 3상 SKYSCRAPER-02 연구가 무진행 생존율의 공동 1차 종결점을 충족하지 못했다고 발표했습니다. 이를 통해 회사는 전 세계적으로 확장할 수 있었습니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE GLOBAL FIBROTIC DISEASE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 GLOBAL FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS
5.1 NORTH AMERICA
5.1.1 U.S.
5.1.2 CANADA
5.2 EUROPE
5.2.1 EUROPEAN UNION (EMA - EUROPEAN MEDICINES AGENCY)
5.2.2 GERMANY (FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES - BFARM)
5.2.3 UNITED KINGDOM (MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY - MHRA)
5.3 ASIA-PACIFIC
5.3.1 JAPAN (PMDA - PHARMACEUTICALS AND MEDICAL DEVICES AGENCY)
5.3.2 CHINA (NMPA - NATIONAL MEDICAL PRODUCTS ADMINISTRATION)
5.3.3 AUSTRALIA (TGA - THERAPEUTIC GOODS ADMINISTRATION)
5.4 LATIN AMERICA
5.4.1 BRAZIL (ANVISA - BRAZILIAN HEALTH REGULATORY AGENCY)
5.4.2 ARGENTINA (ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS, ALIMENTOS Y TECNOLOGÍA MÉDICA - ANMAT)
5.5 MIDDLE EAST AND AFRICA (MEA)
5.5.1 UNITED ARAB EMIRATES (UAE - MINISTRY OF HEALTH AND PREVENTION)
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF FIBROTIC DISEASES
6.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES
6.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES
6.1.4 AWARENESS AND EARLY DIAGNOSIS INITIATIVES
6.2 RESTRAINTS
6.2.1 HIGH COST OF MEDICATION AND TREATMENTS
6.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES
6.3 OPPORTUNITIES
6.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.2 ADVANCEMENTS IN PIPELINE DRUG DEVELOPMENTS
6.3.3 INCREASING STRATEGIC COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES.
6.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES,
7 GLOBAL FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 MEDICATION, BY TREATMENT
7.2.2 MEDICATION, BY DISTRIBUTION CHANNEL
7.3 ORGAN TRANSPLANT
7.4 OXYGEN THERAPY
7.5 OTHERS
8 GLOBAL FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 IDIOPATHIC PULMONARY FIBROSIS
8.3 HEPATIC CIRRHOSIS
8.4 RENAL FIBROSIS
8.5 CUTANEOUS FIBROSIS
8.6 OTHERS
9 GLOBAL FIBROTIC DISEASE TREATMENT MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 ACADEMIC AND RESEARCH INSTITUTES
9.5 OTHERS
10 GLOBAL FIBROTIC DISEASE TREATMENT MARKET, BY REGION
10.1 OVERVIEW
10.2 NORTH AMERICA
10.3 EUROPE
10.4 ASIA PACIFIC
10.5 SOUTH AMERICA
10.6 MIDDLE EAST AND AFRICA
11 GLOBAL FIBROTIC DISEASE TREATMENT MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: GLOBAL
11.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
11.3 COMPANY SHARE ANALYSIS: EUROPE
11.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS
13.4 SANDOZ INTERNATIONAL GMBH
13.4.1 COMPANY SNAPSHOT
13.4.2 COMPANY SHARE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENTS
13.5 ACCORD HEALTHCARE
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 ABBVIE INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 BRISTOL-MYERS SQUIBB COMPANY.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 BIOMX.
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 INTERCEPT PHARMACEUTICALS, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENTS
13.1 KITHER BIOTECH S.R.L.
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENTS
13.11 REDX PHARMA PLC.
13.11.1 COMPANY SNAPSHOT
13.11.2 REVENUE ANALYSIS
13.11.3 PRODUCT PORTFOLIO
13.11.4 RECENT DEVELOPMENTS
13.12 VERONA PHARMA PLC
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
표 목록
TABLE 1 GLOBAL FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 2 GLOBAL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 GLOBAL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 4 GLOBAL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (VOLUME)
TABLE 5 GLOBAL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (ASP)
TABLE 6 GLOBAL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 7 GLOBAL ORGAN TRANSPLANT IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 GLOBAL OXYGEN THERAPY IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 GLOBAL OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 GLOBAL FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 11 GLOBAL IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 GLOBAL HEPATIC CIRRHOSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 GLOBAL RENAL FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 GLOBAL CUTANEOUS FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 GLOBAL OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 GLOBAL FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 17 GLOBAL HOSPITALS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 GLOBAL SPECIALTY CLINICS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 GLOBAL ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 GLOBAL OTHER END-USE IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 GLOBAL FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 22 NORTH AMERICA FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 23 NORTH AMERICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 24 NORTH AMERICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 25 NORTH AMERICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 26 NORTH AMERICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 27 NORTH AMERICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 28 NORTH AMERICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 29 NORTH AMERICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 30 U.S. FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 31 U.S. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 32 U.S. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 33 U.S. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 34 U.S. FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 35 U.S. FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 36 U.S. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 37 CANADA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 38 CANADA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 39 CANADA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 40 CANADA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 41 CANADA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 42 CANADA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 43 CANADA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 44 MEXICO FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 45 MEXICO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 46 MEXICO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 47 MEXICO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 48 MEXICO FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 49 MEXICO FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 50 MEXICO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 51 DOMINICAN REPUBLIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 52 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 53 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 54 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 55 DOMINICAN REPUBLIC FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 56 DOMINICAN REPUBLIC FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 57 DOMINICAN REPUBLIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 58 JAMAICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 59 JAMAICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 60 JAMAICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 61 JAMAICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 62 JAMAICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 63 JAMAICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 64 JAMAICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 65 PANAMA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 66 PANAMA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 67 PANAMA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 68 PANAMA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 69 PANAMA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 70 PANAMA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 71 PANAMA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 72 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 73 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 74 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 75 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 76 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 77 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 78 EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 79 EUROPE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 80 GERMANY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 81 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 82 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 83 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 84 GERMANY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 85 GERMANY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 86 GERMANY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 87 FRANCE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 88 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 89 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 90 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 91 FRANCE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 92 FRANCE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 93 FRANCE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 94 U.K. FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 95 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 96 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 97 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 98 U.K. FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 99 U.K. FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 100 U.K. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 101 ITALY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 102 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 103 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 104 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 105 ITALY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 106 ITALY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 107 ITALY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 108 SPAIN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 109 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 110 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 111 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 112 SPAIN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 113 SPAIN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 114 SPAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 115 RUSSIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 116 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 117 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 118 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 119 RUSSIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 120 RUSSIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 121 RUSSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 122 TURKEY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 123 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 124 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 125 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 126 TURKEY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 127 TURKEY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 128 TURKEY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 129 NETHERLANDS FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 130 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 131 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 132 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 133 NETHERLANDS FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 134 NETHERLANDS FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 135 NETHERLANDS MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 136 SWITZERLAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 137 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 138 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 139 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 140 SWITZERLAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 141 SWITZERLAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 142 SWITZERLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 143 HUNGARY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 144 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 145 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 146 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 147 HUNGARY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 148 HUNGARY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 149 HUNGARY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 150 LITHUANIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 151 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 152 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 153 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 154 LITHUANIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 155 LITHUANIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 156 LITHUANIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 157 AUSTRIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 158 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 159 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 160 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 161 AUSTRIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 162 AUSTRIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 163 AUSTRIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 164 IRELAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 165 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 166 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 167 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 168 IRELAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 169 IRELAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 170 IRELAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 171 NORWAY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 172 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 173 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 174 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 175 NORWAY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 176 NORWAY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 177 NORWAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 178 POLAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 179 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 180 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 181 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 182 POLAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 183 POLAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 184 POLAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 185 REST OF EUROPE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 186 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 187 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 188 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 189 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 190 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 191 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 192 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 193 ASIA-PACIFIC MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 194 JAPAN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 195 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 196 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 197 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 198 JAPAN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 199 JAPAN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 200 JAPAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 201 CHINA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 202 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 203 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 204 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 205 CHINA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 206 CHINA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 207 CHINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 208 INDIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 209 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 210 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 211 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 212 INDIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 213 INDIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 214 INDIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 215 SOUTH KOREA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 216 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 217 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 218 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 219 SOUTH KOREA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 220 SOUTH KOREA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 221 SOUTH KOREA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 222 AUSTRALIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 223 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 224 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 225 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 226 AUSTRALIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 227 AUSTRALIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 228 AUSTRALIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 229 SINGAPORE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 230 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 231 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 232 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 233 SINGAPORE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 234 SINGAPORE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 235 SINGAPORE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 236 THAILAND FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 237 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 238 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 239 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 240 THAILAND FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 241 THAILAND FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 242 THAILAND MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 243 MALAYSIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 244 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 245 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 246 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 247 MALAYSIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 248 MALAYSIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 249 MALAYSIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 250 INDONESIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 251 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 252 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 253 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 254 INDONESIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 255 INDONESIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 256 INDONESIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 257 PHILIPPINES FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 258 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 259 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 260 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 261 PHILIPPINES FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 262 PHILIPPINES FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 263 PHILIPPINES MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 264 VIETNAM FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 265 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 266 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 267 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 268 VIETNAM FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 269 VIETNAM FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 270 VIETNAM MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 271 TAIWAN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 272 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 273 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 274 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 275 TAIWAN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 276 TAIWAN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 277 TAIWAN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 278 REST OF ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 279 SOUTH AMERICA FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 280 SOUTH AMERICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 281 SOUTH AMERICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 282 SOUTH AMERICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 283 SOUTH AMERICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 284 SOUTH AMERICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 285 SOUTH AMERICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 286 SOUTH AMERICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 287 BRAZIL FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 288 BRAZIL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 289 BRAZIL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 290 BRAZIL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 291 BRAZIL FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 292 BRAZIL FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 293 BRAZIL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 294 ECUADOR FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 295 ECUADOR MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 296 ECUADOR MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 297 ECUADOR MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 298 ECUADOR FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 299 ECUADOR FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 300 ECUADOR MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 301 CHILE FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 302 CHILE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 303 CHILE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 304 CHILE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 305 CHILE FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 306 CHILE FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 307 CHILE MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 308 COLUMBIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 309 COLUMBIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 310 COLUMBIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 311 COLUMBIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 312 COLUMBIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 313 COLUMBIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 314 COLUMBIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 315 VENEZUELA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 316 VENEZUELA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 317 VENEZUELA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 318 VENEZUELA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 319 VENEZUELA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 320 VENEZUELA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 321 VENEZUELA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 322 ARGENTINA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 323 ARGENTINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 324 ARGENTINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 325 ARGENTINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 326 ARGENTINA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 327 ARGENTINA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 328 ARGENTINA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 329 PERU FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 330 PERU MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 331 PERU MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 332 PERU MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 333 PERU FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 334 PERU FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 335 PERU MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 336 CURAÇAO FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 337 CURAÇAO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 338 CURAÇAO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 339 CURAÇAO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 340 CURAÇAO FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 341 CURAÇAO FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 342 CURAÇAO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 343 PARAGUAY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 344 PARAGUAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 345 PARAGUAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 346 PARAGUAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 347 PARAGUAY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 348 PARAGUAY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 349 PARAGUAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 350 URUGUAY FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 351 URUGUAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 352 URUGUAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 353 URUGUAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 354 URUGUAY FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 355 URUGUAY FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 356 URUGUAY MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 357 TRINIDAD AND TOBAGO FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 358 TRINIDAD AND TOBAGO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 359 TRINIDAD AND TOBAGO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 360 TRINIDAD AND TOBAGO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 361 TRINIDAD AND TOBAGO FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 362 TRINIDAD AND TOBAGO FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 363 TRINIDAD AND TOBAGO MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 364 REST OF SOUTH AMERICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 365 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 366 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 367 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 368 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 369 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 370 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 371 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 372 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 373 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 374 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 375 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 376 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 377 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 378 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 379 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 380 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 381 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 382 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 383 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 384 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 385 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 386 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 387 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 388 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 389 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 390 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 391 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 392 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 393 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 394 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 395 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 396 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 397 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 398 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 399 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 400 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 401 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 402 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 403 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 404 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 405 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 406 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 407 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 408 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 409 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 410 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 411 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 412 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 413 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 414 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 415 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 416 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 417 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 418 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 419 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 420 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 421 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 422 REST OF MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
그림 목록
FIGURE 1 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 2 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS
FIGURE 5 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE GLOBAL FIBROTIC DISEASE TREATMENT MARKET FROM 2025 TO 2032
FIGURE 14 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL FIBROTIC DISEASE TREATMENT MARKET IN 2025 AND 2032
FIGURE 15 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL FIBROTIC DISEASE TREATMENT MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 16 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR FIBROTIC DISEASE TREATMENT MARKET MANUFACTURERS IN THE FORECAST PERIOD OF 2025 TO 2032
FIGURE 17 MARKET OVERVIEW
FIGURE 18 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 19 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 20 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)
FIGURE 21 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 22 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2024
FIGURE 23 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)
FIGURE 24 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, CAGR (2025-2032)
FIGURE 25 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 26 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2024
FIGURE 27 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 28 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 29 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 30 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 31 GLOBAL FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 32 NORTH AMERICA FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 33 EUROPE FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)
FIGURE 34 ASIA-PACIFIC FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
